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ABSTRACT 
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 The emergence of multidrug-resistant strains of Mycobacterium tuberculosis 
(Mtb) has intensified efforts to discover novel drugs for tuberculosis (TB) treatment.  
Targeting the persistent state of Mtb, a condition in which Mtb is resistant to 
conventional drug therapies, is of particular interest.  Persistent bacteria rely on 
metabolic pathways that are distinct from active infection Mtb as the environmental 
conditions of the persistent state are different (e.g., low nutrient).  Because persistent 
Mtb are forced to survive in a low nutrient environment, a short, two enzyme pathway 
that becomes heavily utilized and upregulated is the glyoxylate shunt.  Since the 
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glyoxylate shunt enzymes are not present in mammals, they make attractive drug targets.  
We are studying malate synthase (MS), one of the enzymes in the glyoxylate shunt.  We 
used computational, biochemical, and cellular techniques to identify potential inhibitors 
of MS.  Crystal structures of MS in complex with inhibitors were used to rationally 
design better MS inhibitors.  MS inhibitors validated via an enzyme activity assay, were 
then tested against whole cells using a non-pathogenic form of mycobacteria, 
Mycobacterium smegmatis.  In this manner, inhibitors against MS have been identified 
and characterized for further development into potential novel antitubercular drugs. 
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CHAPTER I 
INTRODUCTIONa 
 
Tuberculosis (TB) is the leading cause of death worldwide due to an infectious disease, 
killing around 2 million people annually, primarily in developing countries.  Over one-
third of the world’s population is infected with TB with approximately 8 million new 
cases of infection every year.1  TB incidence is also on the rise because of the 
correspondingly high HIV infection rates.  These two diseases progress at faster rates in 
co-infected individuals. 
 Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis, is an 
obligate aerobe whose sole host is humans.  The primary mode of transmission of Mtb is 
through the air in an aerosolized form, most commonly via a cough or sneeze.2  Once in 
the terminal alveoli of the lungs, Mtb is phagocytized by host macrophages.  In this early 
stage of infection, Mtb is able to replicate within non-activated macrophages.2  However, 
the body subsequently mounts a cell-mediated immune response to the growing 
mycobacteria, which includes the activation of macrophages with interferon-γ.3  The 
                                                 
a This thesis follows the style and format of Nature. 
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cell-mediated immune response is sufficient 90-95% of the time in controlling the Mtb 
infection, but not completely eradicating the mycobacteria from the host.4 
 In fact, the remaining mycobacteria will enter into the non-replicating persistence 
phase or the so called latent stage of the infection.  Mtb can reside in alveolar 
macrophages, avoiding the host immune response for an indefinite period of time.  
Activation of such latent mycobacteria can occur anytime later in life, especially when 
the host has become immunocompromised.2 
 Antitubercular drug therapy has existed since the late 1940s,5 but the long time 
course of the drug cocktail required for treatment (6-12 months) often causes low patient 
compliance in completing prescribed regimen.  Another problem is the fact that Mtb can 
survive for extended periods of time in its non-replicative or persistent state.  While in 
this state, Mtb is resistant to conventional forms of chemotherapy.  Patient 
noncompliance coupled with the ability of Mtb to enter the persistence state has 
contributed to the emergence of multidrug-resistant (MDR) and extensively drug-
resistant (XDR) strains of Mtb.  The ineffectiveness of current antituberculars against 
persistent, MDR, and XDR mycobacteria has greatly energized the search for novel anti-
TB drugs, including those that target the persistence state. 
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 In order to target the latent stage of the infection, studies have been performed to 
better understand the extreme intracellular conditions within host macrophages under 
which dormant Mtb reside.  Some of the identified conditions include hypoxia,6 iron 
deficiency,7 low pH,8 and a fatty acid rich carbon pool9,10 all contribute to the altered 
phenotype that Mtb displays in the dormant state.  With the sequencing of the Mtb 
H37Rv genome,11 it has become possible to map and assign specific genes to their 
putative functions.  Using microarray technology, genes that are upregulated in response 
to nutrient starvation12 and latency-like conditions13,14,15,16 have been identified.  The 
complete genomic sequence coupled with microarray technology has been critical for the 
identification of metabolic pathways that are required to support the persistent state in 
Mtb.17 
 One of the changes that occur once Mtb enters the persistent state is an activation 
of the glyoxylate shunt within the tricarboxylic acid (TCA) cycle.18,19  This activation 
facilitates a metabolic shift to acetyl CoA as the primary carbon source, which is the 
product of the β-oxidation of fatty acids.  The glyoxylate shunt consists of two enzymes, 
isocitrate lyase (ICL) and malate synthase (MS), which act as a bypass to the two CO2 
producing steps in the TCA cycle, thus conserving carbon (which can be used for 
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gluconeogenesis) and replenishing TCA cycle intermediates in an anaplerotic fashion.  
The first enzyme in the glyoxylate shunt, ICL, catalyzes the cleavage of isocitrate to 
succinate and glyoxylate.  In the second step, MS condenses glyoxylate and acetyl CoA 
to produce malate.  Since neither ICL nor MS are present in mammals, they have 
become attractive targets for novel anti-TB drug design.20 
 In Mtb, the genes encoding both ICL and MS are upregulated in response to 
macrophage phagocytosis.21,22  It has been reported that an Mtb icl knockout strain was 
able to establish an acute, but not a persistent infection in mice.19  Also, antibodies to 
MS have been discovered in 90% of patients during incipient subclinical tuberculosis.23  
According to Bishai,24 the random insertion of transposons into the Mtb MS gene (glcB, 
annotated Rv1837c)11 resulted in a non-viability under normal growth conditions; in 
contrast, Sassetti25 determined that Mtb MS is not required for tuberculosis infection in 
mice using a similar transposon insertion method.  However, attempts to knockout Mtb 
glcB have been unsuccessful (J. D. McKinney, personal communication).  McKinney 
and colleagues, using Mycobacterium smegmatis (closely related to Mtb, but non-
virulent), determined that the double knockout of glcB and gcl (glyoxylate carboligase, 
not present in Mtb) produced an M. smegmatis strain that was unable to grow on acetate 
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as the sole carbon source, which mimics the macrophage intracellular environment.  
Additionally, supplementation of Mtb glcB into the double knockout M. smegmatis 
strain compensated the knockout phenotype, thus affording the complemented strain 
with the ability to survive on acetate as the sole carbon source (J. D. McKinney, personal 
communication). 
Mtb malate synthase is an 80 kDa, 741 amino acid monomer.  Several crystal 
structure complexes (substrate-, inhibitor-, and product-bound) of Mtb MS have been 
reported,26,27 providing the atomic level details of the Mtb MS active site as well as the 
binding modes of MS ligands.  Using this structural data, inhibitors can be designed to 
inhibit the activity of MS by exploiting its defined molecular structure. 
 To begin drug discovery, a library of compounds resembling the natural ligands 
of an enzyme is assembled and screened for inhibition of enzyme activity to identify so 
called “hits.”  Alternative libraries (often as large as 1-5 million compounds) with a 
broad diversity of chemotypes are also screened so that a large amount of chemical 
space can be sampled against the enzyme active site of interest.  The classical way to 
screen the library in the pharmaceutical industry is to perform a high throughput screen 
(HTS) using a rapid, yet reliable assay to determine potential inhibitors from the library 
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being used.28  Two rounds of HTS were performed by the Southern Research Institute 
(SRI) on Mtb MS (totaling 140,000 compounds).  The compounds in the library were 
then ranked based upon the degree to which they inhibited MS catalytic activity, thus 
providing a preliminary hit list of potential inhibitors to study further. 
 Another method used to identify potential inhibitors for drug targets is to screen 
large libraries of compounds by virtual screening (VS).  VS is an in silico method of 
computationally fitting ligands into protein active sites.  The docking program will use 
an algorithm to predict the binding energy and interaction modes of the various ligands 
in the virtual library, which can then be ranked.  There are many docking algorithms that 
have been developed,29,30,31,32 but DOCK33,34 is used for MS because of its history of 
success with reproducing the ligand binding modes of known crystal structure 
complexes.35,36  With the Mtb MS active site, a virtual library of over 4 million 
compounds was sampled in silico.37  The compounds were then scored based upon 
electrostatic and van der Waals terms, and the generalized Born/solvent accessible 
surface (GB/SA) model, which rewards the burying of non-polar molecules but 
penalizes molecules that carry a formal charge for desolvation.38  The scored and ranked 
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list of VS hits provides a second list of potential inhibitors that can be compared and 
studied further in parallel with the hits from the HTS. 
 The next step is to validate potential inhibitor hits identified from the HTS and 
the VS.  This will be accomplished via a multifaceted approach: First, the inhibitor will 
be tested in vitro against Mtb MS to determine its potency against the enzyme.  Second, 
compounds that have shown promising inhibition in vitro will be assayed for growth 
inhibition against whole cells (M. smegmatis).  This assay will also assess the ability of 
the compound to cross the cell wall of the mycobacteria in order to reach its target (MS) 
as well as assess the specificity of the inhibitor for MS with both knockout and 
overexpressing strains.  In parallel to whole cell testing, attempts will be made to obtain 
the three-dimensional structure of the most potent inhibitors in complex with MS by x-
ray crystallography. 
 Information from the in vitro assays, whole cell assays, and crystal structure 
inhibitor complexes will aid in the structure-activity relationship (SAR) modification of 
validated hit compounds used as a starting point for rational drug design.  This is done to 
help optimize solubility, cell permeability, and favorability of interactions of the 
compound within the active site, thus producing a more specific and potent inhibitor.  
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Such an optimized MS inhibitor could then be used as a lead compound to target Mtb in 
the persistent state. 
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CHAPTER II 
METHODS 
 
Malate synthase expression and purification 
MS was previously cloned in an Escherichia coli pET-15b expression vector with a N-
terminal 6X His tag and a thrombin cleavage site.  The MS overexpression plasmid was 
transformed into BL21(DE3) cells.  Large scale cultures were grown in LB media 37 ºC 
with 50 µg/mL carbenicillin, until an OD600 of 0.6-0.8.  The cultures were then induced 
with 0.5 mM IPTG for 15 h at 20 ºC.  The E. coli containing the MS plasmid cultures 
were then pelleted by centrifugation and resolubilized in Buffer A containing 20 mM 
Tris pH 7.5, 100 mM NaCl, 5 mM imidazole with 50 µg/mL PMSF, 20 µg benzamidine, 
and 50 µg/mL DNase.  The cells were subsequently lysed using a French press 
apparatus; the lysate was then centrifuged and the supernatant was filtered through a 
0.45 µm filter prior to its loading onto a Ni2+ immobile metal affinity chromatography 
(IMAC) column.  After washing with Buffer A, MS was eluted from the column with a 
linear gradient from 0-100% of Buffer B (20 mM Tris pH 7.5, 100 mM NaCl, 500 mM 
imidazole).  The elution fractions were subsequently run on an SDS-PAGE gel to 
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confirm which fractions contained MS (80 kDa).  Fractions containing MS were 
dialyzed against Tris buffer pH 7.5 while being incubated with thrombin (1 unit per 2 
mg MS), in order to cleave the MS His tag.  After dialysis, the protein is again passed 
over the Ni2+ IMAC column, this time with untagged MS found in the flow-through and 
the tag along with the of uncleaved fraction of MS being left bound to the IMAC 
column.  MS is then dialyzed again with the same buffer composition as before and 
concentrated using a 50 kDa molecular weight cut-off 50 mL tube concentrator (Amicon 
Ultra, Millipore). 
 
Malate synthase inhibition assays 
Two assays (“direct” and “coupled”) for MS inhibition were utilized; both monitor the 
co-enzyme A (CoA) released as a product from the chemistry of the MS-mediated 
reaction.  Both assays were carried out using 100 µL overall reaction volumes with MS 
at 92.5 nM being reacted in 20 mM Tris pH 7.5 and 5 mM MgCl2.  All inhibitors (in 
100% DMSO) were added such that the final reaction mixture contained 1% DMSO (1 
µL of stock inhibitor added to the reaction mixture).  Inhibitors were incubated with MS 
in Tris buffer with MgCl2 for 10 min at room temperature before adding the first 
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substrate: 1.25 mM glyoxylate for the direct assay or 0.06 mM acetyl CoA for the 
coupled assay.  The reaction was initiated by the addition of the second substrate: 0.625 
mM acetyl CoA for direct assay or 1.25 mM glyoxylate for the coupled assay. 
 The “direct” assay measures the loss in absorbance at λ = 232 nm due to the 
conversion of acetyl-CoA to CoA. This reaction was continuously monitored for 2 min 
using a Cary 100 spectrometer with a 100 µL quartz window black cuvette.  Reaction 
with a 1% DMSO solution instead of inhibitor was taken as the uninhibited control.  The 
percent inhibition was calculated by comparing the slope/min values (representing the 
enzyme velocity) of an inhibitor trial to the uninhibited control. 
 The “coupled” assay measures the increase in absorbance at λ = 412 nm due to 
the formation of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB)-CoA adduct.39  DTNB is 
injected with glyoxylate at the reaction starting point.  A BMG LABTECH POLARstar 
OPTIMA plate reader in absorbance mode was used to continuously monitor the 
reaction for 2 min per well of a Corning 96 well plastic plate.  The percent inhibition 
was calculated in a similar manner as the direct assay. 
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Mycobacterial growth inhibition assay 
M. smegmatis strains obtained from J. D. McKinney and colleagues were used for a 
mycobacterial growth inhibition assay, also known as whole cell testing.  The first M. 
smegmatis clone has had the M. smegmatis MS (glcB) knocked-out along with 
glyoxylate carboligase (gcl), which is not present in Mtb, in order to create a strain 
unable to grow on acetate as the sole carbon source (M. smegmatis ∆glcB ∆gcl, the “–
MS” strain).  The knockout strain was then complemented with Mtb glcB by genome 
insertion.  The resulting strain (M. smegmatis ∆glcB ∆gcl + M. tuberculosis glcB, the “–
MS + TBMS” strain) displayed a compensated phenotype and was able to grow on 
acetate as the sole carbon source. 
 For this assay, the M. smegmatis cells were grown using two different media.  
The 7H9 media contained Middlebrook 7H9 medium with 0.2% dextrose as the carbon 
source, 0.085% NaCl, and 0.05% Tween 80.  The M9-acetate media contained 1X M9 
salts (Sigma) with 0.5% sodium acetate (pH 7.0) as the carbon source, 0.1 mM CaCl2, 
and 2 mM MgSO4. 
 A 3 mL 7H9 starter culture with 1 µL of glycerol stock in a 10 mL culture tube 
was shaken at 37 °C, reaching an OD600 of ~2 after around 36 h for both the –MS and     
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–MS + TBMS clones.  The –MS culture was then diluted to 0.001 OD600 into 7H9 media 
and the –MS + TBMS culture was diluted to the same OD600 in M9-acetate media. 
 The diluted cultures were then plated into sterile 96 well plates in a tissue culture 
hood.  Then 4 µL of inhibitor were added to the wells, leaving the outer wells with 
diluted culture only.  Serial dilutions of inhibitors in 100% DMSO were tested starting 
from 100 µM to 3.125 µM. 
 The 96 well plates were stored with a set of damp paper towels in a sealed plastic 
bag and incubated at 37 °C.  After 3 d, the results were documented by photographing 
the plate.  To further confirm the level of growth inhibition by color, 5 µL of Alamar 
Blue (Biosource) was added to each well.  After overnight incubation in the dark at room 
temperature, another photograph is taken of the plate (blue indicates no cellular growth 
whereas pink indicates cellular growth).   The lowest concentration of inhibitor required 
to inhibit growth was documented as the MIC. 
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Figure 1.  Mycobacterial growth inhibition assay layout.  These are two of the most 
common mycobacterial growth inhibition assay setups.  Inhibitors can be set in a variety 
of ranges and depending on the plate orientation and serial dilution used.  The cells only 
control in the outer wells helps to prevent evaporation in the drug screening wells. 
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Crystallographic Studies 
Crystals of MS were obtained using the hanging-drop vapor diffusion method.  The 
crystallization condition that produced MS crystals contained 100 mM Tris, 100 mM 
MgCl2, and PEG 3350.  Diffraction quality crystals were obtained in pH ranging from 
7.5-8.5, PEG from 18-22%, and MS concentrations from 5-8 mg/mL. 
 As for obtaining MS crystals with a desired inhibitor, co-crystallization and 
soaking of inhibitors with previously formed MS crystals were attempted.  Crystal 
structures were obtained from crystals soaked with inhibitor starting at a concentration 
of 2 mM in mother liquor.   
 MS crystals were harvested using cryo-loops and flash-cooled in liquid nitrogen 
(using FOMBLIN (Sigma) as a cryoprotectant).  Data were collected both on the home 
radiation source and at the synchrotron at the Advanced Photon Source at Argonne 
National Laboratory.  The home source is an R-axis IV imaging plate system and 
rotating Cu anode x-ray generator equipped with osmic mirrors.  Data were collected 
over 180°, with 0.5° image widths and 2-4 min of exposure time per frame. 
 Indexing and scaling was performed using HKL2006.40  Data were refined via a 
rigid body refinement in Refmac41 of the protein chain only of the previously solved Mtb 
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MS in complex with glyoxylate (PDB #1N8I).  Subsequent refinement cycles were 
performed PHENIX.42  Modeling and viewing of the MS crystal structures was 
performed with WinCoot43 and Chimera44.  Ligand molecules were built using the 
eLBOW portion of PHENIX. 
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CHAPTER III 
MOLECULAR VALIDATION AND IDENTIFICATION OF MALATE 
SYNTHASE INHIBITORS 
 
Malate synthase inhibitor families 
Malate synthase (MS) inhibitor identification occurred through the various methods 
previously mentioned: substrate analog screening, high-throughput screening (HTS), and 
virtual screening (VS).  As MS inhibitors were identified, it was evident that the binding 
pocket of MS selected for a distinct set of chemotypes.  These chemotypes were grouped 
into inhibitor families.  Their molecular identification and study will be described 
throughout the remainder of this chapter.  However, at the time of publication, much of 
the following is proprietary.  Therefore compound structures have been omitted in the 
text, tables, and figures; the compounds will instead be referred to by an assigned 
chemical identification number. 
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PKBA family 
Identification 
The progenitor inhibitor from the PKBA family was originally identified from a 
GlaxoSmithKline screen that tested all molecules within their chemical libraries that 
were similar in structure to reactants, products, or putative transition state compounds of 
MS.  PKBA, standing for phenyl keto butanoic acid, is a phenyl diketo acid that was 
found to inhibit MS in vitro 
Validation with malate synthase enzyme inhibition assay 
Testing PKBA inhibition of MS using the DTNB-coupled in vitro enzyme assay, it 
showed 79% inhibition at 50 µM inihibitor concentration and 29% inhibition at 1 µM.  
Using the direct in vitro enzyme assay, PKBA exhibited 41% inhibition at 1 µM (Table 
1). 
PKBA SAR 
In order to probe the space around PKBA within the MS active site, a structure-activity 
relationship (SAR) study was performed.  This was accomplished by systematically 
modifying the base PKBA structure by decorating it with various functional and alkyl 
groups or substituting whole parts of the molecule for another chemical moiety that 
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would mimic the original group.  The compounds were synthesized in collaboration with 
Dr. Joel Freundlich and Mr. Justin Roberts at Princeton University. 
 Once the PKBA SAR compounds were synthesized by Freundlich and 
colleagues, they were assayed using the DTNB-coupled MS enzyme inhibition assay.  
The results of which are summarized in Table 1.  
 
Table 1.  PKBA SAR compounds and their percent inhibition against MS. 
Compound ID % Inhibition @ 50 µM % Inhibition @ 1 µM 
PKBA 79 29; 41 (d) 
JSF-1030 100 68 
JSF-1031 100 18 
JSF-1032 83 23 
JSF-1034 22 23 
JSF-1038 100 73 
JSF-1039 73 5 
JSF-1040 100 20 
JSF-1041 99 73 
JSF-1042 94 34 
JSF-1044 97 11 
JSF-1043 97 72 
JSF-1047 98 10 
JSF-1048 98 37 
JSF-1049 96 28 
JSF-1050 0 - 
JSF-1051 0 - 
JSF-1053 98 57 
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JSF-1058 99 72 
JSF-1054 12 - 
JSF-1055 0 - 
JSF-1056 0 - 
JSF-1064 30 - 
JSF-1065 95 2 
JSF-1069 25 - 
JSF-1070 22 - 
6679187 0 - 
JSF-1071 22 - 
JSF-1072 63 - 
JSF-1076 12 - 
JSF-1085 0 - 
5238318 0 - 
5238319 0 - 
JSF-1118 0 - 
JSF-1119 0 - 
JSF-1091 0 - 
JSF-1097 20 - 
JSF-1111 0 - 
JSF_1112 0 - 
5314457 0 - 
633739 0 - 
510602 0 - 
107395 49 at 100 µM - 
P51605 0 - 
156548 0 - 
JSF-1123 0 - 
JSF-1124 0 - 
JSF-1125 0 - 
JSF-1126 0 - 
JSF-1128 96 85 
JSF-1130 0 - 
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JSF-1131 0 - 
JSF-1138 0 - 
JSF-1139 0 - 
JSF-1154 0 - 
JSF-1159 25 - 
JSF-1165 0 - 
JSF-1166 0 - 
JSF-1167 88 6 
JSF-1171 0 - 
JSF-1172 0 - 
JSF-1173 48 - 
JSF-1174 37 - 
JSF-1175 50 - 
JSF-1176 28 - 
JSF-1178 19 - 
JSF-1179 17 - 
JSF-1180 13 - 
JSF-1181 100 - 
JSF-1182 99 - 
223875 0 - 
420085 0 - 
NSC401908 0 - 
223595 0 - 
11735636 0 - 
244162 0 - 
245269 0 - 
344830 0 - 
245269 0 - 
74492 0 - 
2756602 0 - 
569815 0 - 
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 Overall, 81 PKBA derivatives were tested: 22 have shown inhibition at least 50% 
inhibition at 50 µM and of those, 7 have shown greater than 50% inhibition at 1 µM.  
Table 2 summarizes the PKBA SAR compounds that showed great activity against MS 
than the parent PKBA. 
 
Table 2.  PKBA SAR compounds with better percent inhibition of MS than PKBA. 
Compound ID % Inhibition @ 50 µM % Inhibition @ 1 µM 
PKBA 79 29 
JSF-1030 100 68 
JSF-1031 100 18 
JSF-1032 83 23 
JSF-1038 100 73 
JSF-1040 100 20 
JSF-1041 99 73 
JSF-1042 94 34 
JSF-1044 97 11 
JSF-1043 97 72 
JSF-1047 98 10 
JSF-1048 98 37 
JSF-1049 96 28 
JSF-1053 98 57 
JSF-1058 99 72 
JSF-1065 95 2 
JSF-1128 96 85 
JSF-1167 88 6 
JSF-1181 100 - 
JSF-1182 99 - 
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 These 19 compounds represent a diverse set of modifications to the parent PKBA 
structure.  Some of these include addition of halogens, alkyl groups, and aryl groups to 
the phenyl ring of PKBA.  The array of acceptable substituents around the phenyl rings 
indicates additional space in the active site of MS around where the phenyl ring binds in 
order to accommodate these compounds that are bulkier than the parent PKBA at that 
location.  As these modifications increased the activity of the compound against MS, 
they could be used to further optimize the activity of PKBA as an eventual antitubercular 
drug. 
 
Enamine family 
Identification 
The progenitor of the enamine family was identified from the HTS performed by SRI.  
The parent compound, 6614887, resembles PKBA, but contains an enamine moiety in 
the middle of the alkyl chain that is linked to a phenyl containing group.   
Validation with malate synthase enzyme inhibition assay 
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Testing 6614887 inhibition of MS using the DTNB-coupled in vitro enzyme assay 
showed 74% inhibition at 50 µM inhibitor concentration (Table 3). 
6614887 SAR 
In order to probe the space around 6614887 within the MS active site, an SAR study was 
performed.  This was accomplished using a two-headed approach: 1) by searching 
chemical databases and 2) by systematically modifying the base 6614887 structure as 
was done with the PKBA family.  Again, the synthesized compounds were produced 
through a collaboration with Freundlich and colleagues. 
 The 6614887 SAR compounds were then assayed to determine the percent 
inhibition using the DTNB-coupled MS enzyme inhibition assay.  The results of which 
are summarized in Table 3. 
 
Table 3.  6614887 SAR compounds and their percent inhibition against MS. 
Compound ID % Inhibition @ 50 µM % Inhibition @ 1 µM 
6614887 74 - 
6193555 89 80 
6083251 0 - 
5238397 78 46 
7265904 70 41 
6173566 4 - 
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5238310 0 - 
NSC29078 0 - 
S425222 0 - 
458295 0 - 
NSC204798 0 - 
NSC87863 0 - 
NSC707051 0 - 
JSF-1127 25 - 
5241933 0 - 
5241916 0 - 
 
 Overall, 15 derivatives of 6614887 were tested: 3 have shown inhibition greater 
than 50% inhibition at 50 µM and of those, 1 has shown greater than 50% inhibition at 1 
µM.  Table 4 summarizes the 6614887 SAR compounds that showed approximately as 
great or greater activity against MS than the parent 6614887.  These 3 compounds 
represent both slight (an alkyl group changed to a halogen) and significant (addition of a 
benzooxazinone group) changes to the parent enamine, 6614887.  Possible explanations 
as to why these modifications to 6614887 are effective include that the active site of MS 
has the sufficient space or flexibility to accommodate these modifications, or that these 
inhibitors are degrading to something that is structurally similar to the PKBA family 
(i.e., smaller compounds).  Determination of whether either of these possibilities is 
accurate is currently ongoing. 
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Table 4.  6614887 SAR compounds with better percent inhibition of MS than 
6614887. 
Compound ID % Inhibition @ 50 µM % Inhibition @ 1 µM 
6614887 74 - 
6193555 89 80 
5238397 78 46 
7265904 70 41 
 
Benzooxazinone family 
Identification 
The progenitor of the benzooxazinone family, 5238397, was identified from a structure 
similarity search based upon the enamine family and its original compound, 6614887.  
5238397 is similar to 6614887 in structure, except that instead of branching from the 
PKBA alkyl chain with an enamine, 5238297 does so with a benzooxazinone moiety. 
Validation with malate synthase enzyme inhibition assay 
As was shown in the enamine family (Tables 3 and 4), 5238397 exhibits 79% inhibition 
of MS at 50 µM and 46% at 10 µM inhibitor concentration.   
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Benzooxazinone SAR 
In order to further explore the potent effects of 5238387, an SAR study was performed.  
This was again accomplished using the two-headed approach of searching chemical 
databases and medicinal chemistry synthesis by Freundlich and colleagues. 
 The 5238397 SAR compounds were then assayed to determine the percent 
inhibition using the DTNB-coupled MS enzyme inhibition assay.  The results of which 
are summarized in Table 5.  
 
Table 5.  5238397 SAR compounds and their percent inhibition against MS. 
Compound ID % Inhibition @ 50 µM % Inhibition @ 1 µM 
5238397 78 46 
JSF-1148 87 61 
JSF-1149 78 56 
JSF-1155 41 38 
JSF-1156 74 32 
JSF-1157 8 0 
JSF-1158 63 20 
JSF-1160 96 8 
JSF-1161 0 - 
JSF-1162 34 0 
JSF-1150 49 14 
5787459 34 - 
5283998 70 - 
5950194 0 - 
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5951393 95 89 
5284534 36 - 
6041664 5 - 
5264312 61 47 
JSF-1177 0 - 
JSF-1170 0 - 
JSF-1185 0 - 
JSF-1186 65 - 
JSF-1188 100 - 
JSF-1189 91 - 
 
 Overall, 23 derivatives of 5238397 were tested: 11 have shown inhibition greater 
than 50% inhibition at 50 µM and of those, 3 have shown greater than 50% inhibition at 
1 µM.  Table 6 summarizes the 5238397 SAR compounds that showed as great or 
greater activity against MS than the parent 5238397.  These 11 compounds primarily 
represent alkyl, aryl, and halogen modifications to the to the phenyl ring of the “PKBA 
portion” of the molecule.  As the benzooxazinone family compounds are bulkier than 
either the PKBA or enamine families, modifications that increase the size of the 
benzooxazinone compounds while increasing their activity indicates that either the MS 
active site is flexible enough to accept such bulky compounds or that the compounds are 
degrading to something smaller or more PKBA-like.  Studies regarding these two 
possibilities are currently ongoing. 
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Table 6.  5238397 SAR compounds with better percent inhibition of MS than 
5238397. 
Compound ID % Inhibition @ 50 µM % Inhibition @ 1 µM 
5238397 78 46 
JSF-1148 87 61 
JSF-1149 78 56 
JSF-1156 74 32 
JSF-1160 96 8 
5283998 70 - 
5951393 95 89 
JSF-1188 100 - 
JSF-1189 91 - 
 
Crystal structures of malate synthase in complex with inhibitors 
Crystallization of inhibitor complexes 
Many different crystallization methods and conditions were originally attempted with 
MS.  Very few conditions were found and only one was reproducible (described in 
Methods chapter).  In hanging drops, MS crystallizes in two forms: a “fast” form that 
crystallizes in about 2 weeks to give crystals in the P41212 space group with two 
molecules per asymmetric unit and a “slow” form that crystallizes over about 4 weeks to 
give crystals in the P43212 space group with one molecule per asymmetric unit.  The fast 
form diffracted poorly (~4 Å), whereas the slow form diffracted well (~ 2 Å) on the 
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home radiation source.  Therefore the ligand studies were performed on the P43212 
crystals. 
 In order to produce MS:inhibitor complex crystals, both co-crystallization and 
soaking experiments were attempted.  Only soaking inhibitors into previously formed 
MS crystals was successful. 
Malate synthase crystal structure in complex with JSF-1040 
A MS crystal structure in complex with JSF-1040 was solved; JSF-1040 is the ortho 
methyl derivative of PKBA.  MS crystals were transferred into a fresh drop of JSF-1040 
(2 mM in mother liquor) for soaking.  The MS crystals were harvested after 24 h by 
flash freezing in liquid N2.  The data were collected on the home radiation source.  The 
data collection and refinement statistics can be found in Table 7. 
 The crystals used for the soaking of JSF-1040 were isomorphous to the 
previously reported MS:glyoxylate structure (PDB # 1N8I), being in the P43212 space 
group and containing one molecule in the asymmetric unit.  Therefore the protein chain 
model from this PDB entry was used for the refinement of the MS:JSF-1040 complex 
data. 
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 The overall fold of the MS:JSF-1040 structure is very similar to both the 
unpublished MS:PKBA complex structure and the published glyoxylate bound structure 
(PDB #1N8I) as the main protein chain does not move (Figure 2). 
 
 
Figure 2.  Superposition of MS:ligand complexes.  The triple superposition of 
MS:JSF-1040 (blue), MS:PKBA (yellow), and MS:glyoxylate (red) demonstrates that 
the overall fold of MS is not altered upon binding of different ligands (shown in space 
fill). 
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Similar to PKBA, JSF-1040 was found to bind within the 12 Å long, cylindrical MS 
active site with its terminal keto group oxygen (2.49 Å) and one of the carboxyl oxygens 
(2.50 Å) coordinating the Mg2+ ion buried at the deep end of the pocket in a bidentate 
fashion (Figure 3).  This bidentate coordination of the Mg2+ ion replaces the same 
coordination of Mg2+ by its substrate (or product, malate), glyoxylate (2.08 Å for the 
carboxylate oxygen and 2.45 Å for the aldehyde oxygen).  Thus by completing the 
octahedral arrangement about the Mg2+ ion, JSF-1040 displaces the substrate and thereby 
competitively inhibits MS.  The remaining four coordinations in both the glyoxylate and 
JSF-1040 complex structures that complete the octahedron around the Mg2+ are two 
conserved water molecules (2.09 and 2.20 Å for glyoxylate and 2.39 and 2.51 Å for JSF-
1040 structures), one of the carboxylate oxygens of Glu434 (2.09 Å for glyoxylate and 
2.36 Å for JSF-1040 structures), and one of the carboxylate oxygens of Asp462 (2.02 Å 
for glyoxylate and 2.37 Å for JSF-1040 structures). 
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Figure 3.  Overlay of magnesium coordination.  The MS inhibitor JSF-1040 
completes the octahedral coordination of magnesium in the crystal structure, displacing 
the natural substrate, glyoxylate.  The green sphere in this figure represents the 
remaining part of the JSF-1040 molecule that has been truncated. 
 
 JSF-1040 also makes additional contacts and interactions within the MS active 
site.  The two keto groups of JSF-1040 each make a hydrogen bond interaction with the 
side-chain of Arg339 (2.91 and 3.08 Å).  The phenyl ring of JSF-1040 lies in the center 
of a hydrophobic portion of the MS active site, being surrounded by Val118, Leu461, 
Met515, Trp541, and Met631.  However, these interactions were expected, as they are 
also found in the MS:PKBA complex structure, with the phenyl ring competing with the 
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pantothenate moiety of CoA.  The ortho methyl group of JSF-1040, its only difference 
from PKBA, provides some insight into why it has demonstrated a higher percent 
inhibition of malate synthase activity than PKBA.  The ortho methyl group of JSF-1040 
projects towards Val118 (3.50 Å), which could serve as a possible hydrophobic 
interaction partner.  This additional hydrophobic interaction may be an indication as to 
how and where PKBA can be modified to increase its efficacy against Mtb MS. 
Malate synthase crystal structure in complex with JSF-1034 
A MS crystal structure complex was also solved with JSF-1034; JSF-1034 is the methyl 
ester of PKBA.  MS crystals were transferred into a fresh drop containing JSF-1034 (2 
mM in mother liquor) for soaking.  The MS crystals were harvested after ~5 d by flash 
freezing in liquid N2.  The data were collected on the home radiation source.  The data 
collection and refinement statistics can be found in Table 7. 
 The crystals used for the soaking were isomorphous to the previously reported 
MS:glyoxylate structure (PDB # 1N8I): they were found to crystallize in the P43212 
space group with one molecule in the asymmetric unit with the same unit cell 
dimensions.  As with the MS:JSF-1040 complex data, the protein chain from this PDB 
entry was used for the refinement of the MS:JSF-1034 complex data.   
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 The overall fold of the MS:JSF-1034 structure is the same as the unpublished 
MS:PKBA structure because the ligand electron density for JSF-1034 reveals the diketo 
acid PKBA coordinated to Mg2+.  Based upon the conditions and the ligand electron 
density, JSF-1034 (ester of PKBA) most probably hydrolyzed to give the parent PKBA 
bound to MS. 
Malate synthase crystal structures in complex with the enamine and benzooxazinone 
families 
X-ray crystal structures of MS in complex with inhibitors from the enamine and 
benzooxazinone families have also been attempted in soaking experiments similar to the 
PKBA family complex structures.  However, just like JSF-1034, the inhibitors from the 
enamine and benzooxazinone families are degraded in the presence of MS and mother 
liquor to give the corresponding keto acid bound in the MS active site.  Further studies to 
attempt to trap an enamine or a benzooxazinone in the intact form have been 
unsuccessful thus far. 
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Table 7.  Data collection and refinement statistics for JSF-1040 and JSF-1034 
complex structures. 
 MS:JSF-1040 MS:JSF-1034 
Data collection   
Unit cell (Å) a = 79.637 
b = 79.637 
c = 226.156 
β = 90.000 
a = 79.095 
b = 79.095 
c = 225.442 
β = 90.000 
Space group P43212 P43212 
Number of molecules per asymmetric unit (Z) 1 1 
Resolution limit (Å) 46.10-2.80 45.90-2.70 
Completeness (%) 96.5 (100.0) 100.0 (99.9) 
I/σ 37.9 (14.7) 32.7 (6.5) 
Rsym
a (%) 7.3 (21.3) 31.0 (83.1) 
Refinement   
Resolution limit (Å) 46.10-2.80 45.90-2.70 
Reflections (working/free) 17122/915 19427/1051 
Rwork
b (%) 17.72 20.22 
Rfree
b (%) 26.90 29.03 
Number of water molecules 523 146 
Disordered residues 28 28 
Average B factor (Å2) for protein, ligand, and 
water molecules 
38.546, 28.977, 
40.012 
36.568, 39.330, 
36.535 
RMS deviations   
Bond length (Å) 0.004 0.006 
Angle distances (°) 0.574 0.754 
Values in parentheses are for high resolution shells. 
a Rsym = ∑h∑i |Ihi - <Ih>|/∑h∑i Ihi, where Ihi is the ith observation of the reflection h, 
whereas <Ih> is the mean intensity of reflection h. 
b Rwork = ∑||Fo| - |Fc|| / |Fo|.  Rfree was calculated with a fraction (5%) of randomly 
selected reflections excluded from refinement. 
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CHAPTER IV 
WHOLE CELL VALIDATION AND IDENTIFICATION OF MALATE 
SYNTHASE INHIBITORS 
 
Whole cell assay rationale 
The M. smegmatis growth inhibition assay, or whole cell assay, was designed to answer 
a couple questions.  First, the ability of a particular inhibitor to cross the cell wall and 
cell membrane of mycobacteria was assessed.  Second, the specificity of a particular 
inhibitor was assessed by the combination of cell growth inhibition results from the three 
strains (-MS, -MS + TBMS, and +OE TBMS; see Methods chapter).  A specific MS 
inhibitor should show no inhibition on the –MS strain for two reasons: there is no MS 
present and 7H9, a full media with dextrose as the carbon source, is the only media on 
which this strain grows.  A specific MS inhibitor should show inhibition on the –MS + 
TBMS strain on M9-acetate media since MS is present and it is being utilized because 
acetate is the only carbon source present.  Finally, a specific MS inhibitor should show 
resistance (a higher MIC) on the +OE TBMS strain as the abnormally high intracellular 
concentrations of MS would compensate the level of inhibition observed. 
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Growth inhibition studies on the PKBA family 
PKBA whole cell activity 
One of the obstacles that PKBA presents as a possible antitubercular drug, is that it lacks 
activity against mycobacteria, beyond the limit of our assay (over 100 µM concentration, 
Table 8).  This is most probably due to the inability of PKBA to cross the cell wall or 
membrane because of its negatively charged carboxylate.  Therefore, part of the 
rationale behind the PKBA SAR was to not only increase the activity of the PKBA 
family against the enzyme, but to also impart the family with activity against whole 
mycobacterial cells (partly by giving them the ability to cross the cell wall or 
membrane).  An example result from the mycobacterial growth inhibition assay is shown 
in Figure 4. 
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Figure 4.  Mycobacterial growth inhibition assay result example.  The plates on the 
left contain the –MS M. smegmatis strain in 7H9 media, whereas the plates on the right 
contain the –MS + TBMS strain in M9-acetate media.  Inhibitors are dispensed in rows 
as shown in Fig. 1.  The unstained plates (top plates) represent mycobacterial growth in 
the presence of inhibitor for 3 days; the Alamar blue stained plates (bottom plates) are on 
the third day and read on the fourth day (see Methods chapter). 
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PKBA SAR whole cell activity 
The results of the growth inhibition studies with the PKBA SAR compounds are 
compiled in Table 8. 
 
Table 8.  Comparison of PKBA SAR compounds activity against MS and against 
M. smegmatis. 
Compound ID % Inhibition @ 50 µM  MIC (µM) for –MS; -MS + TBMS 
PKBA 79 >100; >100 
JSF-1030 100 >50; >50 
JSF-1031 100 >100; 3.125 
JSF-1032 83 >50; >50 
JSF-1034 22 >100; >100 
JSF-1038 100 >100; 12.5 
JSF-1039 73 >100; >100 
JSF-1040 100 >100; 0.195 
JSF-1041 99 >100; 50 
JSF-1042 94 >100; >100 
JSF-1044 97 >50; >50 
JSF-1043 97 >50; >50 
JSF-1047 98 >100; >100 
JSF-1048 98 >100; >100 
JSF-1049 96 >100; >100 
JSF-1050 0 - 
JSF-1051 0 - 
JSF-1053 98 >100; 50 
JSF-1058 99 >100; 25 
JSF-1054 12 >100; >100 
JSF-1055 0 >100; 100 
JSF-1056 0 >100; >100 
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JSF-1064 30 >100; >100 
JSF-1065 95 >50; 3.125 
JSF-1069 25 >100; 100 
JSF-1070 22 >100; >100 
6679187 0 - 
JSF-1071 22 >100; >100 
JSF-1072 63 >100; 100 
JSF-1076 12 >100; >100 
JSF-1085 0 >100; >100 
5238318 0 >50; >50 
5238319 0 >50; >50 
JSF-1118 0 >100; >100 
JSF-1119 0 >100; >100 
JSF-1091 0 >50; >50 
JSF-1097 20 50; >100 
JSF-1111 0 >100; >100 
JSF_1112 0 >100; >100 
5314457 0 >50; >50 
633739 0 >50; >50 
510602 0 >100; >100 
107395 49 at 100 µM - 
P51605 0 - 
156548 0 - 
JSF-1123 0 >100; >100 
JSF-1124 0 >100; 100 
JSF-1125 0 >100; >100 
JSF-1126 0 >100; >100 
JSF-1128 96 >100; 100 
JSF-1130 0 >100; >100 
JSF-1131 0 >100; >100 
JSF-1138 0 100; >100 
JSF-1139 0 >100; >100 
JSF-1154 0 50; 50 
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JSF-1159 25 >100; 50 
JSF-1165 0 100; 100 
JSF-1166 0 >100; 6.25 
JSF-1167 88 >100; 12.5 
JSF-1171 0 100; 12.5 
JSF-1172 0 >100; >100 
JSF-1173 48 50; 3.125 
JSF-1174 37 50; <3.125 
JSF-1175 50 25; 50 
JSF-1176 28 25; 50 
JSF-1178 19 50; <3.125 
JSF-1179 17 50; 3.125 
JSF-1180 13 25; <3.125 
JSF-1181 100 >100; <3.125 
JSF-1182 99 >100; <3.126 
sig-223875 0 - 
420085 0 - 
NSC401908 0 - 
223595 0 - 
11735636 0 - 
244162 0 - 
245269 0 - 
344830 0 - 
245269 0 - 
74492 0 - 
2756602 0 - 
569815 0 - 
 
 Of the 81 PKBA SAR compounds tested, 17 showed specific inhibition of MS or 
inhibition on the –MS + TBMS M9-acetate strain only (Table 9).  These 17 compounds 
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represent primarily positional modifications on the phenyl ring of PKBA, including both 
alkyl groups and halogens.  Generally, these observations correlate well with the 
observations from the enzyme inhibition assays: modifications about the phenyl ring of 
PKBA, specifically alkyl groups and halogens, are not only tolerated, but also favored 
against both the enzyme and mycobacterial cells. 
 
Table 9.  PKBA SAR compounds exhibiting acetate-specific inhibition of M. 
smegmatis. 
Compound ID % Inhibition @ 50 µM  MIC (µM) for –MS; -MS + TBMS 
PKBA 79 >100; >100 
JSF-1031 100 >100; 3.125 
JSF-1038 100 >100; 12.5 
JSF-1040 100 >100; 0.195 
JSF-1041 99 >100; 50 
JSF-1053 98 >100; 50 
JSF-1058 99 >100; 25 
JSF-1055 0 >100; 100 
JSF-1065 95 >50; 3.125 
JSF-1069 25 >100; 100 
JSF-1072 63 >100; 100 
JSF-1097 20 50; >100 
JSF-1124 0 >100; 100 
JSF-1128 96 >100; 100 
JSF-1138 0 100; >100 
JSF-1154 0 50; 50 
JSF-1159 25 >100; 50 
JSF-1165 0 100; 100 
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JSF-1166 0 >100; 6.25 
JSF-1167 88 >100; 12.5 
JSF-1171 0 100; 12.5 
JSF-1173 48 50; 3.125 
JSF-1174 37 50; <3.125 
JSF-1175 50 25; 50 
JSF-1176 28 25; 50 
JSF-1178 19 50; <3.125 
JSF-1179 17 50; 3.125 
JSF-1180 13 25; 25 
JSF-1181 100 >100; <3.125 
JSF-1182 99 >100; <3.126 
 
The ortho position effect 
Identification of ortho position effect against mycobacterial cells 
One of the most interesting results to arise from the whole cell experiments was an 
observation about the position effect of substituents on the phenyl ring of PKBA.  When 
the same modification was made to the three different positions on the PKBA phenyl 
ring (ortho, meta, or para), three different MIC values were observed.  Table 10 shows 
an example of this phenomenon. 
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Table 10.  The position effect of the methyl group on the PKBA phenyl ring. 
Compound ID Modification 
% Inhibition @ 
50 µM 
% Inhibition @ 
1 µM 
 MIC (µM) for –MS; 
-MS + TBMS 
PKBA - 79 29; 41 (d) >100; >100 
JSF-1040 ortho Me 100 20 >100; 0.195 
JSF-1041 meta Me 99 73 >100; 50 
JSF-1042 para Me 94 34 >100; >100 
 
 As can be seen in Table 10, the position of a methyl group on the phenyl ring of 
PKBA plays both a factor of the potency of the compound against the enzyme as well as 
against mycobacterial cells, but a different factor in each case.  The ortho (JSF-1040), 
para (JSF-1042), and meta (JSF-1041) methyl positions, respectively, become 
increasingly more active against the MS in the coupled assay.  However, the ortho, meta, 
and para methyl positions, respectively, become increasingly worse in activity against 
mycobacterial cells. 
 A possible explanation of this effect is the presence of a mycobacterial 
membrane transporter that specifically recognizes the ortho methyl group in preference 
to the meta or para methyl group.  In order to see if this ortho methyl effect can be 
extended to other modifications at this ortho position, several other PKBA SAR 
compounds can be compared (Table 11). 
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Table 11.  The position effect of modifications to the PKBA phenyl ring. 
Compound ID Modification 
% Inhibition 
@ 50 µM 
% Inhibition @ 
1 µM 
 MIC (µM) for –MS; 
-MS + TBMS 
PKBA - 79 29; 41 (d) >100; >100 
JSF-1030 2-naphthyl 100 68 >50; >50 
JSF-1031 1-naphthyl 100 18 >100; 3.125 
JSF-1032 para-Br 83 23 >50; >50 
JSF-1038 ortho-Br 100 73 >100; 12.5 
JSF-1043 meta-Br 97 72 >50; >50 
JSF-1053 para-Et 98 57 >100; 50 
JSF-1058 meta-Et 99 72 >100; 25 
JSF-1167 ortho-Et 88 6 >100; 12.5 
 
 The data in Table 11 demonstrate that the ortho modification (or “ortho-like” 
modification in the case of the 1-naphthyl derivative JSF-1031) consistently inhibits 
growth of mycobacterial cells better than the meta or para position modifications.  This 
is in contrast to the data shown for the enzyme inhibition assay where the meta position 
is consistently the best (or tied for the best) against the enzyme. 
 Mycobacterial growth inhibition studies for the enamine and benzooxazinone 
families are ongoing.  These studies include further investigation of the ortho position 
effect, and whether the probable uptake effect can be seen with the enamine and 
benzooxazinone families. 
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CHAPTER V 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The Mtb persistence enzyme, malate synthase, has been studied with various 
biochemical, computational, and cellular approaches.  These studies were initiated 
because of attractiveness of Mtb MS as a potentially novel antitubercular drug target.  
Not only is the enzyme MS not found in mammals, but attempts to knockout Mtb MS 
have been unsuccessful, indicating a possible essential role to Mtb.  The discovery of a 
potent inhibitor against MS would help to validate the essentiality of MS.  These studies 
have identified several inhibitor families upon which further SAR studies have been 
performed. 
 The PKBA family SAR has yielded 19 inhibitors for the enzyme assay and 17 
inhibitors for the whole cell assay that perform better than the parent PKBA, out of the 
81 compounds tested.  Similarly, the enamine family SAR has produced 3 inhibitors (out 
of 15 tested) and the benzooxazinone family SAR has produced 8 inhibitors (out of 22 
tested) that exhibit a higher percent inhibition of MS than the parent enamine (6614887) 
or benzooxazinone (5238397), respectively. 
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 The crystallization and determination of PKBA family inhibitors in complex with 
MS were successful.  JSF-1040 was found to bind in a competitive manner, displacing 
the substrate glyoxylate, as PKBA does.  However, JSF-1040 contains an additional 
hydrophobic interaction with Val118 via its methyl group at the ortho position on the 
phenyl ring.  JSF-1034 was found to hydrolyze to the parent PKBA and bind in the same 
orientation as PKBA.  The means of hydrolysis (e.g., buffer conditions) of JSF-1034 are 
currently under study. 
 Further structural studies are ongoing with the PKBA family and especially the 
enamine and benzooxazinone families.  These studies will help elucidate the possible 
novel binding modes of the enamine and benzooxazinone family members.  These new 
interactions will be exploited in future SAR and rational drug design studies. 
 The mycobacterial growth inhibition studies with the PKBA family yielded an 
interesting result: the position of the modification on the phenyl ring of PKBA 
effectively fine-tunes the level of inhibition of the compound against M. smegmatis.  The 
ortho position on the phenyl ring was found to give exceptionally better MIC values than 
compared to the meta or para positions. 
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 Studies are currently ongoing for the testing of the enamine and benzooxazinone 
families in the mycobacterial growth inhibition assay.  These results may lead to a better 
understanding of the effect of a modification at the ortho position of the phenyl ring, 
including potential explications as to the source of this effect. 
 The discovery of a potent inhibitor of Mtb MS through biochemical, 
computational, and cellular approaches would lead to refinement of that hit into a “lead” 
compound.  Lead compounds are then subjected to animal studies as a measure of their 
toxicity and efficacy.  Progress to this stage leaves hope for the development of an 
antitubercular drug against the persistent Mtb via inhibition of MS. 
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